Who
Michael Thomas Henderson
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Apogee Therapeutics; Director, Spyre Therapeutics; Director, ARYA Sciences Acquisition Corp IV; Chief Business Officer, BridgeBio Pharma.
In numbers
- Trades disclosed
- 200
- Buys
- 1
- Sells
- 41
- Bought
- $119K
- Sold
- $80.2M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 1 Jul 2019
- Last trade
- 3 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —920,941 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —387,012 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —357,036 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —387,012 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —357,036 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —253,016 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —253,016 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —920,941 | filing |
| 10 Jul 2026filed 10 Jul 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code G | —75,046 at $0.00 | filing |
| 10 Jul 2026filed 10 Jul 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code G | —75,046 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.7M20,000 at $133.63 | filing |
| 8 Jul 2026filed 10 Jul 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.7M20,000 at $133.63 | filing |
| 22 Jun 2026filed 24 Jun 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $10.6M80,000 at $132.54 | filing |
| 22 Jun 2026filed 24 Jun 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $10.6M80,000 at $132.54 | filing |
| 22 Jun 2026filed 23 Jun 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.0M20,000 at $100.00 | filing |
| 22 Jun 2026filed 23 Jun 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.0M20,000 at $100.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $557K6,770 at $82.21 | filing |
| 10 Jun 2026filed 12 Jun 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $634K7,654 at $82.78 | filing |
| 10 Jun 2026filed 12 Jun 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K1,080 at $84.18 | filing |
| 10 Jun 2026filed 12 Jun 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $134K1,577 at $85.19 | filing |
News
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)SYRE · themarketsdaily.com · 19 Oct 2026Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026SYRE · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Michael Thomas Henderson; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.